search
Back to results

Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation (ESGC)

Primary Purpose

Hypertension, Blood Pressure, Endothelial Function

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Korean Red Ginseng
Korean Red Ginseng (Panax ginseng)
Cornstarch
Korean Red Ginseng (Panax Ginseng)
Sponsored by
Unity Health Toronto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Hypertension focused on measuring Ginseng, Korean Red Ginseng, Ginsenoside, Flow Mediated Dilation, Endothelial Function, Hypertension

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age: between 18 and 70 years of age
  • Healthy individuals (absence of major illnesses)

Exclusion Criteria:

  • Primary hypertension (defined by the use of antihypertensive agents or a seated systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure greater than 90mmHg)
  • Secondary hypertension (defined as SBP greater than 180mmHg and DBP greater than 110mmHg)
  • Grade 3 hypertension (defined as SBP greater than 180mmHg and DBP greater than 110mmHg)
  • Diabetes
  • Chronic kidney disease
  • Liver disease
  • Estrogen-sensitive cancer
  • Heavy alcohol use
  • Bleeding disorders
  • Planned surgery
  • Angina
  • CHF
  • Coronary revascularization
  • Peripheral vascular disease
  • Coronary/cerebrovascular event in the last 6 months
  • Prescriptions of MAO inhibitors, SSRIs, diuretics, sympathomimetics, herbal therapies, medication affecting nitric oxide synthesis, and/or anticoagulent medications within the last 6 months
  • Sensitivity to any of the ingredients in the treatments or placebo
  • Chronic use of or frequent prescriptions for NSAIDs
  • Women of childbearing potential must not be pregnant or breast-feeding

Sites / Locations

  • St. Michael's Hospital Clinical Nutrition and Risk Factor Modification Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Arm Label

1

2

3

4

Arm Description

Placebo capsules (3g)

Whole Korean Red Ginseng root (3g)

Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root

Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root

Outcomes

Primary Outcome Measures

Flow-mediated dilation of the brachial artery

Secondary Outcome Measures

Augmentation Index
Nitric Oxide and Cyclic GMP

Full Information

First Posted
August 1, 2008
Last Updated
January 5, 2017
Sponsor
Unity Health Toronto
Collaborators
Heart and Stroke Foundation of Canada
search

1. Study Identification

Unique Protocol Identification Number
NCT00728221
Brief Title
Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation
Acronym
ESGC
Official Title
Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
November 2007 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Unity Health Toronto
Collaborators
Heart and Stroke Foundation of Canada

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Ginseng has been used for many years in a wide array of anecdotal medicinal properties. Animal and limited clinical research points to the vascular effects of Korean Red Ginseng (KRG). The present project aims to assess the efficacy of KRG and contribution of its factionated components on various indices of vascular function in healthy individuals. Our primary objective is to compare the acute effects of KRG and placebo on endothelial function. Moreover, our secondary objective is to evaluate the effect of isolated KRG factions on arterial stiffness, blood pressure and vasoactive markers. We hypothesize that (1) consumption of KRG will cause an improvement in endothelial function in healthy individuals, as compared to placebo; (2) consumption of KRG will cause an improvement in arterial stiffness and blood pressure in healthy individuals, as compared to placebo; (3) the ginsenoside faction of KRG is primarily responsible for the anticipated vascular effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Blood Pressure, Endothelial Function
Keywords
Ginseng, Korean Red Ginseng, Ginsenoside, Flow Mediated Dilation, Endothelial Function, Hypertension

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Placebo Comparator
Arm Description
Placebo capsules (3g)
Arm Title
2
Arm Type
Experimental
Arm Description
Whole Korean Red Ginseng root (3g)
Arm Title
3
Arm Type
Experimental
Arm Description
Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root
Arm Title
4
Arm Type
Experimental
Arm Description
Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root
Intervention Type
Dietary Supplement
Intervention Name(s)
Korean Red Ginseng
Other Intervention Name(s)
Kyonggi-do Farm, C. A. Meyer
Intervention Description
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea. Dosage form: whole root in capsules (3g)
Intervention Type
Dietary Supplement
Intervention Name(s)
Korean Red Ginseng (Panax ginseng)
Other Intervention Name(s)
Kyonggi-do Farm, C. A. Meyer
Intervention Description
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea. Dosage form: total ginsenoside fraction in capsules
Intervention Type
Dietary Supplement
Intervention Name(s)
Cornstarch
Intervention Description
Placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Korean Red Ginseng (Panax Ginseng)
Other Intervention Name(s)
Kyonggi-do Farm, C. A. Meyer
Intervention Description
Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea. Dosage form: total polysaccharide fraction (panaxans) in capsules
Primary Outcome Measure Information:
Title
Flow-mediated dilation of the brachial artery
Time Frame
Start and finish of each treatment arm
Secondary Outcome Measure Information:
Title
Augmentation Index
Time Frame
Start and finish of each treatment arm
Title
Nitric Oxide and Cyclic GMP
Time Frame
Beginning of and 3 hours into clinical visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age: between 18 and 70 years of age Healthy individuals (absence of major illnesses) Exclusion Criteria: Primary hypertension (defined by the use of antihypertensive agents or a seated systolic blood pressure greater than or equal to 140mmHg or diastolic blood pressure greater than 90mmHg) Secondary hypertension (defined as SBP greater than 180mmHg and DBP greater than 110mmHg) Grade 3 hypertension (defined as SBP greater than 180mmHg and DBP greater than 110mmHg) Diabetes Chronic kidney disease Liver disease Estrogen-sensitive cancer Heavy alcohol use Bleeding disorders Planned surgery Angina CHF Coronary revascularization Peripheral vascular disease Coronary/cerebrovascular event in the last 6 months Prescriptions of MAO inhibitors, SSRIs, diuretics, sympathomimetics, herbal therapies, medication affecting nitric oxide synthesis, and/or anticoagulent medications within the last 6 months Sensitivity to any of the ingredients in the treatments or placebo Chronic use of or frequent prescriptions for NSAIDs Women of childbearing potential must not be pregnant or breast-feeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vladimir Vuksan, PhD
Organizational Affiliation
St. Michael's Hospital, University of Toronto
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alexandra Jenkins, PhD
Organizational Affiliation
Unity Health Toronto
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Michael's Hospital Clinical Nutrition and Risk Factor Modification Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5C 1N8
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
24758417
Citation
Jovanovski E, Peeva V, Sievenpiper JL, Jenkins AL, Desouza L, Rahelic D, Sung MK, Vuksan V. Modulation of endothelial function by Korean red ginseng (Panax ginseng C.A. Meyer) and its components in healthy individuals: a randomized controlled trial. Cardiovasc Ther. 2014 Aug;32(4):163-9. doi: 10.1111/1755-5922.12077.
Results Reference
background
PubMed Identifier
20134405
Citation
Jovanovski E, Jenkins A, Dias AG, Peeva V, Sievenpiper J, Arnason JT, Rahelic D, Josse RG, Vuksan V. Effects of Korean red ginseng (Panax ginseng C.A. Mayer) and its isolated ginsenosides and polysaccharides on arterial stiffness in healthy individuals. Am J Hypertens. 2010 May;23(5):469-72. doi: 10.1038/ajh.2010.5. Epub 2010 Feb 4.
Results Reference
result

Learn more about this trial

Evaluation and Standardization of Ginseng and it's Components for Blood Pressure Regulation

We'll reach out to this number within 24 hrs